Vor Biopharma (NYSE:VOR) Given “Buy” Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Vor Biopharma (NYSE:VOR) in a research note published on Friday morning,Benzinga reports. They currently have a $17.50 target price on the stock.

A number of other research analysts have also recently commented on the company. Robert W. Baird lowered their price target on Vor Biopharma from $22.00 to $14.00 and set an “outperform” rating on the stock in a report on Friday. Barclays lowered their price target on Vor Biopharma from $10.00 to $3.00 and set an “overweight” rating on the stock in a report on Wednesday, August 14th. Finally, JMP Securities reissued a “market outperform” rating and issued a $12.00 price target on shares of Vor Biopharma in a report on Friday, September 6th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, Vor Biopharma presently has an average rating of “Buy” and a consensus target price of $11.36.

Vor Biopharma Stock Up 5.4 %

VOR stock opened at $1.01 on Friday. Vor Biopharma has a twelve month low of $0.63 and a twelve month high of $3.14. The stock has a market cap of $69.08 million, a P/E ratio of -0.61 and a beta of -0.40. The business’s 50-day moving average price is $0.80 and its 200-day moving average price is $1.06.

Vor Biopharma (NYSE:VOR) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.40) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.40). On average, equities research analysts expect that Vor Biopharma will post -1.51 earnings per share for the current fiscal year.

Institutional Trading of Vor Biopharma

A number of large investors have recently added to or reduced their stakes in the company. Rosalind Advisors Inc. bought a new stake in Vor Biopharma in the 3rd quarter worth approximately $54,000. Exchange Traded Concepts LLC increased its stake in Vor Biopharma by 40.8% in the 3rd quarter. Exchange Traded Concepts LLC now owns 165,805 shares of the company’s stock worth $116,000 after acquiring an additional 48,017 shares during the last quarter. Cubist Systematic Strategies LLC bought a new stake in Vor Biopharma in the 2nd quarter worth approximately $53,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Vor Biopharma during the 2nd quarter valued at approximately $63,000. Finally, Hsbc Holdings PLC increased its position in shares of Vor Biopharma by 177.0% during the 2nd quarter. Hsbc Holdings PLC now owns 49,038 shares of the company’s stock valued at $51,000 after purchasing an additional 31,333 shares during the last quarter. Institutional investors own 97.29% of the company’s stock.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.